Scinai Immunotherapeutics Financials

Scinai Immunotherapeutics Ltd

SCNINASDAQ

Trade with Public

$0.7524

-0.15-16.54%

最終更新: Oct 16, 7:07 PM

$0.7623

-0.14-15.44%

概要ニュース業績予想イベント財務センチメント比較株式レポート

Scinai Immunotherapeutics Financials

Scinai Immunotherapeutics (SCNI) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Scinai Immunotherapeutics H1 Net Income $1.6M Vs Loss $4.1M Prior Year; Revenues $949K Up From $773K YoY; Continues To Pursue ~$5M In CDMO Revenues For 2026

Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDTJERUSALEM, Aug. 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical

Benzinga Newsdesk

PRO
Scinai Immunotherapeutics FY EPS $(3.56), Sales $1.311M Up From $658.000K YoY

Scinai Immunotherapeutics (NASDAQ:SCNI) reported quarterly losses of $(3.56) per share. The company reported $1.311 million in sales this quarter. This is a 99.24 percent increase over sales of $658.000 thousand the

Benzinga Newsdesk

PRO
Scinai Revenues For Six Months Ended Jun. 30 $773K vs $284K YoY

Benzinga Newsdesk

PRO
Scinai Immunotherapeutics 2024 Revenue $658K

Benzinga Newsdesk

PRO
Scinai Immunotherapeutics Q3 EPS $0.0021 Up From $(0.002) YoY, Sales $168K

Benzinga Newsdesk

Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July

Avi Kapoor

Scinai Immunotherapeutics Ltd

Scinai Immunotherapeutics Financials

Earnings & Guidance News

PRO
Scinai Immunotherapeutics H1 Net Income $1.6M Vs Loss $4.1M Prior Year; Revenues $949K Up From $773K YoY; Continues To Pursue ~$5M In CDMO Revenues For 2026

PRO
Scinai Immunotherapeutics FY EPS $(3.56), Sales $1.311M Up From $658.000K YoY

PRO
Scinai Revenues For Six Months Ended Jun. 30 $773K vs $284K YoY

PRO
Scinai Immunotherapeutics 2024 Revenue $658K

PRO
Scinai Immunotherapeutics Q3 EPS $0.0021 Up From $(0.002) YoY, Sales $168K

Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July

ニュース

パートナーシップ

ベンジンガ・グローバル

Scinai Immunotherapeutics Financials

Earnings & Guidance News

PRO
Scinai Immunotherapeutics H1 Net Income $1.6M Vs Loss $4.1M Prior Year; Revenues $949K Up From $773K YoY; Continues To Pursue ~$5M In CDMO Revenues For 2026

PRO
Scinai Immunotherapeutics FY EPS $(3.56), Sales $1.311M Up From $658.000K YoY

PRO
Scinai Revenues For Six Months Ended Jun. 30 $773K vs $284K YoY

PRO
Scinai Immunotherapeutics 2024 Revenue $658K

PRO
Scinai Immunotherapeutics Q3 EPS $0.0021 Up From $(0.002) YoY, Sales $168K

Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July

Scinai Immunotherapeutics Ltd

Scinai Immunotherapeutics Financials

Earnings & Guidance News

PROScinai Immunotherapeutics H1 Net Income $1.6M Vs Loss $4.1M Prior Year; Revenues $949K Up From $773K YoY; Continues To Pursue ~$5M In CDMO Revenues For 2026

PROScinai Immunotherapeutics FY EPS $(3.56), Sales $1.311M Up From $658.000K YoY

PROScinai Revenues For Six Months Ended Jun. 30 $773K vs $284K YoY

PROScinai Immunotherapeutics 2024 Revenue $658K

PROScinai Immunotherapeutics Q3 EPS $0.0021 Up From $(0.002) YoY, Sales $168K

Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July

ニュース

パートナーシップ

ベンジンガ・グローバル

Scinai Immunotherapeutics Financials

Earnings & Guidance News

PROScinai Immunotherapeutics H1 Net Income $1.6M Vs Loss $4.1M Prior Year; Revenues $949K Up From $773K YoY; Continues To Pursue ~$5M In CDMO Revenues For 2026

PROScinai Immunotherapeutics FY EPS $(3.56), Sales $1.311M Up From $658.000K YoY

PROScinai Revenues For Six Months Ended Jun. 30 $773K vs $284K YoY

PROScinai Immunotherapeutics 2024 Revenue $658K

PROScinai Immunotherapeutics Q3 EPS $0.0021 Up From $(0.002) YoY, Sales $168K

Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July

PRO
Scinai Immunotherapeutics H1 Net Income $1.6M Vs Loss $4.1M Prior Year; Revenues $949K Up From $773K YoY; Continues To Pursue ~$5M In CDMO Revenues For 2026

PRO
Scinai Immunotherapeutics FY EPS $(3.56), Sales $1.311M Up From $658.000K YoY

PRO
Scinai Revenues For Six Months Ended Jun. 30 $773K vs $284K YoY

PRO
Scinai Immunotherapeutics 2024 Revenue $658K

PRO
Scinai Immunotherapeutics Q3 EPS $0.0021 Up From $(0.002) YoY, Sales $168K

PRO
Scinai Immunotherapeutics H1 Net Income $1.6M Vs Loss $4.1M Prior Year; Revenues $949K Up From $773K YoY; Continues To Pursue ~$5M In CDMO Revenues For 2026

PRO
Scinai Immunotherapeutics FY EPS $(3.56), Sales $1.311M Up From $658.000K YoY

PRO
Scinai Revenues For Six Months Ended Jun. 30 $773K vs $284K YoY

PRO
Scinai Immunotherapeutics 2024 Revenue $658K

PRO
Scinai Immunotherapeutics Q3 EPS $0.0021 Up From $(0.002) YoY, Sales $168K